Drug intelligence / Profile preview

Nankai Univ. STING compound (Rp,Rp)-10

Development stage: Unknown
Lead developer: Nankai University

Overview

Nankai Univ. STING compound (Rp,Rp)-10: sourced facts only. name: "(Rp,Rp)-10 represents a promising next-generation STING agonist with potent systemic antitumor immunity and durable therapeutic effects." [DOI:10.1158/1538-7445.am2026-7465]; target: "(Rp,Rp)-10 represents a promising next-generation STING agonist with potent systemic antitumor immunity and durable therapeutic effects." [DOI:10.1158/1538-7445.am2026-7465]; developer: "Nankai University, Tianjin, China." [DOI:10.1158/1538-7445.am2026-7465]

Targets

STING (Stimulator of interferon genes protein)

Beyond the preview

Go deeper on Nankai Univ. STING compound (Rp,Rp)-10.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Nankai Univ. STING compound (Rp,Rp)-10.